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Abstract
Personalized medicine seeks to identify the right dose of the right drug for the right patient at the 
right time. Typically, individualization of therapy is based on the pharmacogenomic make-up of 
the individual and environmental factors that alter drug disposition and response. In addition to 
these factors, during pregnancy a woman’s body undergoes many changes that can impact the 
therapeutic efficacy of medications. Yet, there is minimal research regarding personalized 
medicine in obstetrics. Adoption of pharmacogenetic testing into the obstetrical care is dependent 
on evidence of analytical validity, clinical validity, and clinical utility. Here, we briefly present 
information regarding the potential utility of personalized medicine for treating the obstetric 
patient for pain with narcotics, hypertension, and preterm labor and discuss the impediments of 
bringing personalized medicine to the obstetrical clinic.
Obstetrics is a discipline focused on the care of women during pregnancy, an inherently 
normal phase of life. Unlike other medical specialties, obstetric care providers oversee a 
natural process which has been successfully navigated by women for thousands of years, 
even before modern medicine. Over time, care for the patient with abnormal pregnancy or 
medical complications of pregnancy has been added to the spectrum of care provided by 
obstetricians. These conditions are often corrected through procedural interventions on the 
mother or fetus, or through medical management.
Perhaps as a consequence of the perception of normalcy and concerns for harming the fetus, 
only a limited number of therapies have been developed to treat the complications of 
pregnancy. Medications approved by the US Food and Drug Administration (FDA) for use 
in pregnancy fall into a small number of major categories: tocolytics, antiemetics, labor 
induction agents, and a few others. In comparison to many other fields of medicine, the rate 
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of approval of new medications for obstetrical indications has been slow. 
Uncharacteristically, the past four years has seen the FDA approval of 2 medications 
indicated for use in pregnancy: hydroxyprogesterone caproate (Makena®, Ther-Rx 
Corporation) and doxylamine + pyridoxine (Diclegis®, Duchesnay USA, Inc.). However, 
both medications represent a repackaging of previously accepted therapies. 
Hydroxyprogesterone caproate has been used since the late-20th century as a progestational 
agent, though it was not until the turn of the century that usage became more widespread1. 
Diclegis® is a variant of Bendectin®, a medication previously approved for treatment of 
hyperemesis gravidarum in pregnancy. The story of Bendectin® has been previously 
outlined extensively and represents an important lesson in the dangers inherent in fear about 
teratogenicity from medication usage in pregnancy2. The components of these two 
medications have been used off-label for years, though safety concerns still lingered among 
clinicians. The FDA approval of Makena® and Diclegis® formalize the acceptance of use of 
the medications in pregnancy. The approval of these two agents, with a long history of off-
label use in pregnancy, also accentuates the difficulty in developing drugs to treat conditions 
in pregnancy. Truly innovative development of drug therapy in obstetrics leading to drug 
approval by the FDA has not occurred in many years.
Beyond medications used for obstetric indications, pregnant women are also exposed to 
treatments for medical co-morbidities complicating pregnancy. The selection of a 
medication to treat a given pathology (e.g., lupus, hypertension, seizure disorders) rests on 
evidence of efficacy in the non-pregnant population, balanced against teratogenicity or 
correlation with poor obstetric outcomes. Historically, the FDA has maintained a pregnancy 
drug rating system to summarize the known information on risk of drug usage in pregnancy. 
This A-B-C-D-X letter rating has been misinterpreted by many clinicians and has led to the 
withholding of therapy due to the perceived risk of medications within specific classes3. As 
early as 1997, the FDA recommended changes in drug labeling to move towards a 
descriptive rating system to encourage clinicians to more carefully consider the evidence 
supporting the use of a drug in pregnancy4,5.
The variability in patient response to medications that occurs in general, and to an even 
greater extent in pregnancy, has been a factor in the increased perception of risk during this 
period. In addition to baseline genetic diversity, the physiologic changes of pregnancy can 
accentuate inter-individual differences in drug response. These physiologic changes can alter 
the ADME (absorption, distribution, metabolism, elimination) properties of a drug and its 
resultant efficacy. For example, 17α-hydroxyprogesterone caproate administered to prevent 
recurrent preterm delivery may have a decreased effect in women with particular 
progesterone receptor subtypes6. The variability in patient response to 17α-
hydroxyprogesterone caproate may be further compounded by inter-individual differences in 
creatinine clearance, volume of distribution, or other contributing factors during pregnancy. 
Betamethasone is provided to promote fetal maturity in cases of anticipated preterm 
delivery; however, the effects are not uniform in all treated fetuses. Recently, genetic 
variations have been identified that may influence the success of this intervention7.
The unpredictability of adverse events related to patient variability in obstetrics has led to 
undesirable consequences. Providers favor older drugs with minimal risks over newer, 
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untested medications. Litigation resulting from drug-related adverse events has further 
dampened enthusiasm to provide appropriate therapy to pregnant patients. Paradoxically, 
few drugs are routinely monitored during pregnancy despite the increased variability. 
Therapeutic drug monitoring is limited by a lack of available clinical assays for most drugs.
Despite these obstacles, developments in obstetric therapeutics now occur against the 
background of a growing body of pharmacogenomic data on drugs in general, which can be 
used to improve the therapeutic range of the available therapies for pregnant women and 
their children. Persuasive arguments have been advanced in support of using genetic 
information to guide the choice of drug, the dose involved and the need for monitoring8,9. 
The FDA has included pharmacogenomic information in over 130 drug labels with over 50 
genes implicated in drug efficacy or safety10. A large portion of pharmacogenomics 
information in drug labels relates to drug metabolism enzymes and many are in the form of 
“black box” warnings. It is estimated that one fourth of all outpatients receive one or more 
drugs with pharmacogenomic information in the label for that drug11.
Personalized Medicine in Obstetrics
The pregnant woman differs in many aspects from the non-pregnant patient. Not only are 
there longitudinal physiologic changes that effect drug pharmacokinetics12,13, but the 
genetic make-up of the fetus differs from that of the mother. While in some cases fetal 
genetics may play a role in fetal response to drugs14, maternal genetics will likely play the 
larger role in determining disposition and response. In addition, although 
pharmacogenomics is increasingly recognized as a key determinant of response for drugs, 
few studies have been conducted in pregnant women. Thus, as with many areas of obstetrics, 
we must extrapolate knowledge of pharmacogenomics to this orphaned population.
The FDA labeling for several drugs commonly prescribed by obstetricians contains 
pharmacogenomics information (Table 1). Below, we provide examples of pharmacogenetic 
information of potential value to pregnant women and their health care providers, including 
data relevant to the use of narcotics to treat severe pain and the treatment of hypertension 
and preterm labor.
Narcotics
Peripartum pain is commonly treated by narcotic pain relievers, such as codeine and 
hydrocodone. These prodrugs require biotransformation through CYP2D6 metabolism to 
their active moieties, morphine and hydromorphone, respectively. CYP2D6 activity is 
induced during pregnancy15. In addition, more than 80 pharmacogenomic variants have 
been reported for CYP2D6 (http://www.cypalleles.ki.se.cypalleles.com), many of which 
alter the activity of the enzyme (Table 2). Approximately 7% of Caucasians have a variant 
that leads to a CYP2D6 poor metabolizer (PM) phenotype, which results in reduced enzyme 
activity. For instance, these individuals have reduced capacity to convert codeine to 
morphine16,17 and do not obtain adequate pain relief from codeine. Conversely, about 2–3% 
of Caucasians possess multiple copies of active CYP2D6 alleles, leading to an ultrarapid 
metabolism (UM) phenotype. In these individuals, codeine is rapidly converted to morphine, 
potentially leading to toxicity16,17. While rare, cases of death in UM individuals treated with 
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clinical doses of codeine have been reported18–20. In some of these individuals, the presence 
of a variant that reduces the activity of UDP-Glucuronosyltransferase-2B7 (UGT2B7), the 
enzyme responsible for inactivation of morphine, may have also contributed to the toxic 
concentrations of morphine. After the report of an infant death associated with the CYP2D6 
UM genotype of a breastfeeding mother taking codeine for post-Cesarean pain relief21, the 
U.S. FDA issued a Public Health Advisory cautioning women on the use of narcotic 
analgesics during breastfeeding22. Additionally, the Clinical Pharmacogenomics 
Implementation Consortium (CPIC) has issued guidelines on the use of codeine with respect 
to CYP2D6 genotype17. While hydrocodone and oxycodone undergo similar metabolic 
activation via CYP2D6, there are not adequate data regarding the consequences of PM or 
UM phenotype for use of these agents.
Antihypertensives
Commonly used to treat hypertension in pregnancy, metoprolol is metabolized primarily by 
CYP2D6. A meta-analysis of studies in non-pregnant individuals recently identified a 15-
fold difference in apparent oral clearance of metoprolol between ultrarapid and poor 
metabolizers for CYP2D623. In addition to the pharmacogenetic variation of CYP2D6, the 
enzyme’s increased activity in pregnancy15 may necessitate increased doses of metoprolol 
compared to those used in non-pregnant women.
Similar to metoprolol, labetalol’s half-life is decreased during pregnancy24. A recent study 
found that gestational age and lean body weight were significantly associated with oral 
clearance25. Labetalol is cleared predominantly by glucuronidation through UGT1A1 and 
UGT2B726. The documented increase in UGT1A1 expression during pregnancy has been 
attributed to the induction of UGT1A1 by progesterone26. A study in healthy Chinese males 
was unable to confirm an association with UGT1A1 genotype, but did find higher plasma 
concentrations of labetolol in CYP2C19*2*2 expressers, accounting for 60% of the total 
variation in plasma exposure27, indicating that oxidative metabolism may be an important 
component of labetalol’s clearance. To our knowledge, no studies of pharmacogenomics of 
labetalol in pregnancy have been conducted. Hydralazine, a vasodilator available for the 
treatment of hypertension since 1952, is one of the few medications available to treat 
hypertensive emergencies in pregnancy, including severe preeclampsia. Hydralazine is 
primarily metabolized and cleared from the body by the N-acetyltransferase enzyme28. 
Based on a small study examining the metabolism of caffeine, N-acetyltransferase activity 
does not appear to significantly change during pregnancy29. That said, functional 
polymorphisms in the genes encoding the two human n-acetyltransferases, NAT1 and NAT2, 
are common28. Over 50% of Caucasians are slow acetylators, leading to increased plasma 
concentrations of hydralazine, and therefore, increased risk of toxicity.
Treatment of Preterm Labor
While the β2 adrenergic receptor agonists, e.g. ritodrine, terbutaline, and hexoprenaline, 
have fallen out of favor in the treatment of preterm labor due to increased adverse effects 
and limited efficacy, it is important to note the potential for interindividual variability in 
response to the agents. There is evidence that polymorphisms in the β2 adrenergic receptor 
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(ADRB2) are protective against preterm delivery30–32. In addition, Landau et al. found that 
homozygosity in Arg16 improved the tocolytic response to hexoprenaline33. Additional 
studies are needed to examine the effect of polymorphisms in ADRB2 on response to β2 
adrenergic receptor agonists. However, clinicians should be aware of the potential 
contribution of pharmacogenetics to the interindividual variability in response to these 
drugs, which may necessitate the increase of dose to improve efficacy or decreasing the dose 
to prevent adverse drug events.
The calcium channel blocker nifedipine is metabolized by CYP3A enzymes in the liver and 
gastrointestinal tract. CYP3A activity increases during pregnancy15,34, resulting in higher 
clearance of nifedipine35. Since CYP3A activity is highly variable within and between 
individuals, it is not surprising that plasma concentrations of nifedipine are highly variable 
(30–70%) among pregnant women. Studies of nifedipine in pregnant women have found that 
CYP3A5 genotype and concomitant administration of CYP3A inhibitors, such as 
clarithromycin, erythromycin, and fluoxetine, are associated with altered nifedipine 
pharmacokinetics36,37. In addition to the potential effect of polymorphisms in drug 
metabolizing enzymes, genetic polymorphisms in components of the L-type calcium channel 
(CANC1C, CACN1D) and the large-conductance calcium and voltage-dependent potassium 
channel ß1 subunit gene (KCNMB1) are associated with responsiveness and risk of 
cardiovascular side effects in patients taking calcium channel blockers for 
hypertension38–40. At present, it is unknown if these variants influence the tocolytic 
response to nifedipine.
The prostaglandin inhibitor indomethacin is widely used as a tocolytic, and is primarily 
metabolized through O-demethylation by CYP2C941. The activity of CYP2C9 is increased 
during pregnancy12,42,43. Additionally, CYP2C9 is highly polymorphic with 10–20% of 
Caucasians and up to 6% of blacks expressing poor metabolism phenotypes arising from 
CYP2C9*2 or CYP2C9*3 alleles44. It is estimated that 50% of indomethacin clearance is 
due to CYP2C9, and poor metabolism status is predicted to increase exposure by 1.8-fold in 
non-pregnant individuals45. However, to our knowledge, no clinical studies have examined 
the effect of CYP2C9 genotype in pregnancy or on indomethacin tocolysis.
While its effectiveness as a tocolytic is marginal46, magnesium sulfate is commonly used for 
fetal neuroprotection47–49. Magnesium sulfate is cleared through renal filtration with 
homeostatisis maintained by reabsorption through a variety of passive and active transport 
mechanisms50. To our knowledge, the pharmacogenomics of magnesium sulfate have not 
been examined.
Betamethasone and, less commonly, dexamethasone are administered to women at risk of 
preterm birth to promote fetal lung maturity. Several studies have examined 
pharmacogenomics of corticosteroids, although few have focused on this indication. 
Pharmacogenomic studies in asthma have associated variants in several genes in the 
corticosteroid pathway with responsiveness to inhaled corticosteroids: corticotropin 
releasing hormone receptor 1 (CRHR1)51; T-box 21 (TBX21)52; neurokinin receptor 2 
(NK2R)52; Stress-induced phosphoprotein 1 (STIP1)53; dual specificity phosphatase 1 
(DUSP1)54; the Low affinity IgE receptor, FCER2 (rs28364072)55; and the glucocorticoid-
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induced transcript 1 gene (GLCC1)56. In a study of 62 preterm neonates born to mothers 
who had received betamethasone, the I105V variant in glutathione-S-transferase-P1 (GST-
P1) was associated with reduced occurrence of respiratory distress syndrome57. GST-P1 is 
the primary GST isoform expressed in the placenta, and this variant leads to reduced enzyme 
activity, which could result in increased fetal concentrations of betamethasone. Haas et al. 
conducted a pharmacogenomic study examining SNPs in the betamethasone metabolic 
pathway in cohort of 109 pregnant women and 117 maternal-neonatal pairs treated with 
betamethasone for fetal lung maturation14. A multivariate analysis controlling for various 
demographic and clinical factors found a statistically significant association of maternal 
CYP3A5 genotype, maternal N43C1 (rs41423247), fetal ADCY9 (rs2230739), and fetal 
CYP3A7*1E with neonatal respiratory distress syndrome (RDS). Of these genes, fetal 
CYP3A7*1E genotype was found to have the highest odds ratio of 23.68 (95% CI: 1.33–
420.6) for development of RDS14, potentially due to an increased clearance of 
betamethasone by CYP3A7. Additional analysis of this same cohort identified SNPs in 
maternal or fetal importin 13 (IPO13) that were associated with outcomes such as surfactant 
use and bronchopulmonary dysplasia7.
Clinical Utility of Pharmacogenomic Tests in Obstetrics
Despite the widespread availability of a large number of pharmacogenetic tests58, the 
widespread use of pharmacogenomic testing is inherently dependent on the generation of 
evidence that supports it. Three key elements of evidence are required: analytical validity, 
clinical validity and clinical utility.
Analytical validity refers to the reproducibility of a given test in the laboratory. In contrast, 
clinical validity refers to the ability of a test to act as a robust predictor of a clinical 
parameter, for example, a pharmacokinetic variable that summarizes drug exposure such as 
the plasma half-life or area under the plasma drug concentration-time curve (AUC). Clinical 
utility assesses the ability of a test to reliably predict a change in treatment necessitated by 
the result of the genetic test. The treatment change may include a change in drug, dose, or 
monitoring59. While analytical validity is widely available and accepted for most clinically 
available pharmacogenetic tests, clinical validity and utility have been less well studied or 
documented59.
These criteria should be met in pregnant women prior to applying pharmacogenomics 
testing to obstetric therapeutics. However, research to document clinical utility will require 
significant effort and breadth of vision, since clinical utility has not been established in cases 
specific to pregnant patients. That said, this is also the case for many drugs used both in 
obstetrics and pediatrics where drugs are often prescribed “off label” because of the lack of 
trials in the appropriate populations. However, as with other aspects of drug therapy in 
pregnancy, it may be acceptable to extrapolate pharmacogenetic information from the non-
pregnant population. For example, it is reasonable to presume that the pharmacogenetic 
testing for HLA-B*5701 that is standard of care before the use abacavir in HIV patients to 
prevent potentially fatal and disfiguring abacavir-related skin hypersensitivity60 should also 
be provided to pregnant women with HIV.
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Economic considerations are also important. While many pharmacogenetic tests are now 
available in the United States for less than a few hundred dollars, this is not universally the 
case. Some institutions and laboratories continue to charge thousands of dollars for tests that 
cost much less to carry out. The economic value of most pharmacogenetic tests, even in 
general practice, remains a notably understudied area61–63. There is an increasing realization 
that pharmacogenetic testing may be a means that can be used by large health care systems 
to improve the quality of care and save costs by reducing the significant human and 
economic damage brought about by adverse drug reactions64, and ensuring that appropriate 
therapies are given to the patients most likely to benefit.
Conclusion
Obstetrical patients have long been an orphaned population with respect to medical 
advancement. However, a recent directive from the Institute of Medicine’s committee on 
Women and Health Research that promotes the inclusion of pregnant women in clinical 
studies65 and the establishment of the NICHD’s Obstetric and Fetal Pharmacology Research 
Unit Network symbolize a recognition that the nearly four million women who are pregnant 
annually in the United States66 are not immune to diseases necessitating drug therapy. While 
obstetrics may trail behind other medical specialties in the development of personalized 
medicine, in some cases knowledge obtained from other therapeutic areas can be 
extrapolated to the pregnant population. Additionally, the principles of analytic, clinical, and 
perhaps economic validity of pharmacogenomic testing developed in other populations can 
guide the implementation of personalized medicine to obstetrical patients. Development of 
models that bring together an individual’s pharmacogenetic make-up and the physiologic 
changes associated with pregnancy may eventually guide individualization of drug selection 
and dosage during pregnancy to optimize drug benefit in the obstetric patient.
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Table 1
Pharmacogenomic information in the FDA label of drugs commonly administered to pregnant women.
Drug Name Gene Pharmacogenomic Information in FDA Label
Tramadol CYP2D6 Concentrations in PM’s were 20% higher than in EM’s
Codeine CYP2D6 Respiratory depression and death have occurred in UM children and in breast-fed infants 
whose mothers are UM’s
Hydralazine NAT1-2 Mean absolute bioavailability varies from 10–26% with higher percentages in PM’s; 
EM’s have lower exposure
Metoprolol CYP2D6 EM’s who concomitantly take CYP2D6 inhibitors and PM’s have increased 
concentrations, decreasing metoprolol’s cardioselectivity
Glyburide G6PD Hemolytic anemia linked to G6PD deficiency
Esomeprazole & Omeprazole CYP2C19 Induction of CYP3A4 by St. John’s wort led to 37.9% decrease in omeprazole AUC in 
PM’s and a 43.9% decrease of AUC in EM’s
Lansoprazole CYP2C19 Concomitant administration with tacrolimus may increase whole blood levels of 
tacrolimus, especially in transplant patients who are IM’s or PM’s. Coadministration to 
EM’s taking clopidogrel reduced the AUC of clopidogrel’s active metabolite by 14%.
Pantoprazole CYP2C19 PM’s have elimination half-life of 3.5 to 10 hours; in EM’s, 71% of the dose is excreted 
in urine and 18% through biliary excretion
Metoclopramide CYB5R1-4 G6PD Patients with NADH-cytochrome b5 reductase deficiency are at an increased risk of 
developing methemoglobinemia and/or sulfhemoglobinemia when metoclopramide is 
administered. In patients with G6PD deficiency who experience metoclopramide- 
induced methemoglobinemia, methylene blue treatment is not recommended.
Nitrofurantoin G6PD Hemolytic anemia linked to G6PD deficiency
Citalopram CYP2C19 Cmax and AUC increased by 68% and 107% in PM’s. Highest recommended dose in 
PM’s is 20 mg/d due to risk of QT prolongation
Fluoxetine CYP2D6 PM’s have higher concentrations of S-fluoxetine, and lower concentrations of S-
norfluoxetine, at steady state. There is no effect of CYP2D6 metabolism status on 
pharmacodynamics of fluoxetine.
Paroxetine CYP2D6 In EM’s, concomitant administration of paroxetine increased the AUC and Cmax of 
atomoxetine.
CYP2D6: cytochrome P450 2D6; NAT1-2: N-acetyltransferase 1 and 2; G6PD: glucose-6-phosphate dehydrogenase; CYP2C19: cytochrome P450 
2C19; CYB5R1-4: cytochrome b5 reductase 1–4; PM: poor metabolizer; EM: extensive metabolizer; UM: ultra-rapid metabolizer; AUC: area 
under the plasma concentration-time curve; Cmax: maximum plasma concentration
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Table 2
Common CYP2D6 alleles, functional effect, and frequency in African Americans and Caucasiansa
Allele Activity
Allele Frequency, Mean(Range)%b
African Americans Caucasians
*1 Normal 40 (30–83) 54 (28–83)
*2 Normal 14 (4–29) 27 (10–40)
*3 Non-functional 0.3 (0–0.6) 1 (0–3)
*4 Non-functional 6.2 (4–8) 18 (10–33)
*5 Non-functional 6 (2–9) 3 (0–7)
*6 Non-functional 0.2 (0–1) 1 (0–3)
*9 Reduced 0.5 (0–1) 2 (0–5)
*10 Reduced 4 (3–8) 3 (0.4–15)
*17 Reduced 18 (13–26) 0.3 (0–1.1)
*36 Non-functional 0.6 (0–1) 0
*41 Reduced 9 (2–15) 9 (4–14)
*1×N Increased 0.4 (0–1.2) 0.8 (0–4)
*2×N Increased 1.6 (0.1–2) 1.3 (0–6)
*4×N Non-functional 2 (0.3–4) 0.3 (0–1)
aAdapted from Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 
2014 Update.17
bhttp://www.pharmgkb.org/download.action?filename=CYP2D6_allele_frequency_table_R2.xlsx, updated August 2013.
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